Skip to main content
. 2018 May 24;36(22):3161–3168. doi: 10.1016/j.vaccine.2017.05.094

Fig. 3.

Fig. 3

IgG antibody titers against the model antigen (BSA) from mouse sera plotted as geometric mean over time on a log2 scale. (A) Low-dose Formulations C & G compared to a series of three dose-matched bolus BSA injections and (B) high-dose Formulation E compared to its dose-matched bolus control. Bolus BSA was injected at 0, 4, and 8 weeks in the control groups.